EPISODE · Jun 2, 2025 · 14 MIN
ASCO 2025: The leaders of Daiichi-Sankyo discuss new data for the ADC ENHERTU in 1L HER2+ breast cancer and 2L HER2+ gastric cancer, plus new targets that are emerging
from BiotechTV - News · host BiotechTV
Global Head of Oncology Ken Keller walks us through the company's ASCO data and highlights other future catalysts to watch, which new Global CEO Hiroyuki Okuzawa discusses the company's long-term plans to be a top 10 oncology company.
Embed this episode
Ready to play
ASCO 2025: The leaders of Daiichi-Sankyo discuss new data for the ADC ENHERTU in 1L HER2+ breast cancer and 2L HER2+ gastric cancer, plus new targets that are emerging
0:00
14:55
1×
No transcript for this episode yet
Similar Episodes
No similar episodes found.
Similar Podcasts
No similar podcasts found.
Frequently Asked Questions
How long is this episode of BiotechTV - News?
This episode is 14 minutes long.
When was this BiotechTV - News episode published?
This episode was published on June 2, 2025.
Can I download this BiotechTV - News episode?
Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!